Clinical Trials
PPMI Enrolling Adults to Study How Parkinson's Starts
The Parkinson's Progression Markers Initiative (PPMI) is recruiting volunteers with and without Parkinson's disease age 18 and older in the U.S. This landmark study explores how brain disease starts and changes in people of all backgrounds. Participants receive free smell tests and ongoing monitoring. The goal: earlier diagnosis and better treatments. *
michaeljfox.orgGene Therapy AB-1005 Aims to Slow Parkinson's Progression
The REGENERATE-PD study is testing a one-time gene therapy (AB-1005) that helps the brain produce more GDNF, a protective protein. Participants ages 45–75 with a Parkinson's diagnosis of 4–10 years who experience motor fluctuations despite medication are eligible. The therapy involves a surgical procedure to deliver the gene directly into the brain, with follow-up visits every 3–6 months for up to five years. Sponsored by AskBio, a subsidiary of Bayer. *
michaeljfox.orgStem Cell Therapy DSP-1083 Entering Phase I/II Trials
A clinical study is testing whether stem cells (DSP-1083) can be transplanted into the brain to grow into dopamine-producing cells. The goal is to replace cells lost to Parkinson's. Adults ages 40–72 who still have symptoms while taking their regular medication may qualify. Sponsored by Sumitomo Pharma America. *
michaeljfox.orgOral Drug NEU-411 Targets Early Parkinson's Progression
A Phase II trial is testing NEU-411, a once-daily oral pill designed to slow disease progression in people with early Parkinson's symptoms who are not yet on dopamine therapy. The drug targets overactivity in the LRRK2 pathway, which includes people with LRRK2 gene mutations plus approximately 30% of other Parkinson's patients. Screening includes testing for LRRK2 pathway overactivity. Sponsored by Neuron23. *
michaeljfox.org
Breakthrough Treatments
Japan Approves World's First Stem Cell Therapy for Parkinson's
On March 6, 2026, Japan approved AMCHEPRY — the world's first iPS stem cell therapy for Parkinson's. Unlike drugs that only manage symptoms, this treatment replaces the dopamine-producing brain cells that Parkinson's destroys. Made from stem cells that are transplanted into the brain, this moves cell replacement from the lab into real clinical use for the first time ever. Currently for people whose symptoms aren't controlled by current medications. More studies required. *
allaboutparkinsons.comNew Pill GT-02287 Shows Promise Slowing Disease Progress
Gain Therapeutics announced early results for GT-02287 — a drug that fixes the broken GCase enzyme. When this enzyme fails, toxic proteins build up in brain cells and kill them. Early data showed the drug reached the brain, lowered toxic buildup to normal levels, and improved or stabilized patients' movement scores. Larger trials are planned for late 2026. If it works, this could be one of the first treatments that actually fights the disease instead of just masking symptoms. *
allaboutparkinsons.comGPR6 Inhibitor Cuts OFF Time in Phase 2 Trials
On April 9, 2026, Cerevance announced that solengepras (CVN424) — a once-daily oral GPR6 inhibitor — demonstrated meaningful reductions in daily OFF time and improvements in sleep-related symptoms across two Phase 2 trials. Results were presented at the American Academy of Neurology 2026 Annual Meeting. *
markets.businessinsider.com
Lifestyle Interventions
New Study Tests Combined Lifestyle Approach for Parkinson's
The SENSS study is a 12-month randomized controlled trial at Radboud University Medical Center in the Netherlands testing an integrated lifestyle approach for people with Parkinson's. The intervention combines five domains: stress management, exercise, nutrition, sleep, and self-management. Participants receive personalized coaching from certified lifestyle coaches over 12 months. The study will enroll 256 participants. *
frontiersin.orgLifestyle Medicine Review Highlights Diet, Exercise, and Sleep Role
A comprehensive review published in PMC (2025) highlights how lifestyle medicine — including physical activity, nutrition, sleep, stress management, and social interaction — plays an increasingly important role in Parkinson's care. The review found that Mediterranean-DASH dietary approaches, regular exercise, and sleep optimization may help modulate disease risk and progression. Physical activity is the most well-established lifestyle intervention for Parkinson's, with strong evidence for improving motor and non-motor symptoms. *
pmc.ncbi.nlm.nih.govSleep Disorders Affect Up to 88% of Parkinson's Patients
A review published in PMC found that sleep disturbances are among the most prevalent non-motor symptoms in Parkinson's, affecting up to 88% of patients. The review emphasizes that treating sleep disorders can significantly enhance quality of life and potentially slow disease progression. Addressing sleep should be a standard part of Parkinson's care. Exercise also has documented benefits for sleep quality in Parkinson's patients. *
pmc.ncbi.nlm.nih.gov
Emerging Research
Human Cell Model Shows How Alpha-Synuclein Damages Mitochondria
Researchers at the University of Cambridge and Lund University developed a human neuron model of Parkinson's that replicates key pathology. The study, published in Nature Communications Biology (2026), shows how early alpha-synuclein accumulation leads to mitochondrial dysfunction — a key driver of neuron death in Parkinson's. The model was used to test peptide inhibitors B36D and S62, offering a new platform for drug discovery. *
nature.comBlarcamesine Shows Treatment Effects in Advanced Alpha-Synuclein Model
Anavex Life Sciences presented data at the AD/PD 2026 Conference showing significant treatment effects of blarcamesine in a new advanced alpha-synuclein model of Parkinson's disease. The model addresses both alpha-synuclein accumulation (the protein that builds up in Parkinson's brains) and noradrenergic degeneration — a combination that mimics key aspects of the disease. This advances the understanding of how blarcamesine may work across multiple Parkinson's pathology targets. *
anavex.comWearable Sensors Track Levodopa Levels and Tremor in Real Time
Two March 2026 studies demonstrated wearable devices are advancing toward practical Parkinson's monitoring. Sweat sensors on 32 patients tracked levodopa levels and matched them to tremor intensity in 79% of cases. A separate three-year study caught worsening gait, balance, and daily function even when standard clinic tests appeared stable. This suggests continuous wearable monitoring may outperform periodic office visits for tracking disease progression and treatment effectiveness. *
allaboutparkinsons.com
This report is for informational purposes only. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.